Abstract
1 min readObjective: to evaluate the correlation between 25(OH)D levels in CIS patients and the development of Clinically Defined Multiple Sclerosis (CDMS). Background the risk of developing MS is related to both genetic and environmental factors. Vitamin D could play a role in CDMS conversion. Design/Methods: this is a single-center retrospective study. 107 CIS patients hospitalized from 2000 to 2009 at San Raffaele Hospital were recruited. We evaluated baseline serum 25(OH)D levels as well as clinical, brain MRI, Multimodal Evoked Potential and CSF data. Results: 21% patients developed CDMS at 12-month follow-up, 36% at 2-year follow-up and 44% at 5 year follow-up. A statistically significant inverse correlation between 25(OH)D levels and the risk to develop CDMS (OR 2.197) was observed. The difference between serum 25(OH)D levels in patients who developed CDMS and patients who did not, is statistically higher during summertime (p Conclusions: the presence of at least 3 negative clinical/paraclinical prognostic factors highly predicts short term conversion to CDMS (OR 5.39, p Disclosure: Dr. Martinelli has received personal compensation for activities with Biogen Dompe, Merck Serono, Bayer Schering, Teva, and Sanofi Aventis as a speaker. Dr. Dalla Costa has nothing to disclose. Dr. Colombo has nothing to disclose. Dr. Dalla Libera has nothing to disclose. Dr. Leocani has nothing to disclose. Dr. Furlan has nothing to disclose. Dr. Rubinacci has nothing to disclose. Dr. Filippi has received personal compensation for activities with ECTRIMS, MSIF, MS Ireland, US NMSS, Bayer-Schering, Biogen-Dompe AG, Genmab, Merck Serono, Pepgen Corporation, Teva, and Sanofi-Aventis. Dr. Filippi has received research support from Teva, Bayer-Schering and Genmab. Dr. Comi has received personal compensation for activities with Novartis, Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Inc., Merck Serono, Bayer Schering, and Biogen Dompe.
Discussion(0)
No comments yet. Be the first to comment.